Reporter brief
Narrative review describes necroptosis-senescence pathway in kidney fibrosis with preclinical but untranslated senolytic evidence.
What happened
This narrative review synthesized peer-reviewed literature on necroptosis, cellular senescence, and renal tubulointerstitial fibrosis, searching PubMed, Web of Science, and Embase through July 2026. The authors describe a proposed mechanistic continuum where mitochondrial DNA released from necroptotic tubular cells drives glycolytic reprogramming and a senescence-associated secretory phenotype that amplifies fibrosis. Senolytics are mentioned among existing targeted strategies showing "preclinical efficacy" but the review does not report actual senolytic trial data, effect sizes, or clinical translation success.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Systematic review; In vitro.
Renal tubular epithelial cells and interstitial fibroblasts in the context of chronic kidney disease progressing to tubulointerstitial fibrosis
- Design
- Systematic review
- Sample
- —
- Journal
- Frontiers in Medicine
- Published
- Sep 3, 2026
Effect size
Not recorded.
Caveats
- Assessment: Pending.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.